The Advanced Cardiovascular Protocol — ApoB, Lp(a) & Fibrinolysis
A lipid-particle-focused cardiovascular protocol built around ApoB as the primary endpoint. Bergamot inhibits cholesterol synthesis, berberine upregulates LDL receptors, EPA-forward omega-3 covers triglycerides and residual risk, and nattokinase optionally addresses the fibrinolytic limb. What to measure, realistic effect sizes, and where prescription drugs remain the right answer.
Daily Schedule
Timing and dosage for each step
Before breakfast and dinner
1000 mg
1,000 mg/day of a bergamot polyphenol fraction standardised to 38%+ polyphenols, split or single dose before meals. The ApoB layer — brutieridin and melitidin partially inhibit HMG-CoA reductase. Expect 15–25% LDL reduction per the meta-analysis, not the 40% from the best-case early trial.
With each main meal
1500 mg
500 mg three times daily. The LDL-receptor layer: berberine upregulates hepatic LDL-receptor expression and activates AMPK — a mechanism complementary to bergamot's synthesis inhibition. ⚠️ Inhibits CYP3A4/2D6 — check every prescription drug against it; skip in pregnancy.
Morning, with a fat-containing meal
2000 mg
2 g combined EPA+DHA, EPA-forward if triglycerides are elevated. REDUCE-IT used 4 g of pure EPA in statin-treated patients — the only supplement-adjacent molecule in this stack with a cardiovascular outcome trial behind it.
Between meals, once daily — optional layer
100 mg
100 mg (2,000 FU) on an empty stomach. The fibrinolytic layer, and the most honest label in the stack is 'experimental': acute coagulation effects are real, the long-term structural trial was null. ⚠️ Never combine with anticoagulants or antiplatelets without physician sign-off; stop 2 weeks before surgery.
Protocol Overview
This protocol treats cardiovascular risk the way lipidology now does: as a particle-count problem measured by ApoB, plus a thrombotic limb that lipids don't capture. Each layer earns its place by mechanism:
- Citrus bergamot — partial HMG-CoA reductase inhibition via brutieridin and melitidin. The synthesis layer.
- Berberine — upregulates hepatic LDL-receptor expression, pulling ApoB particles out of circulation. The clearance layer.
- Omega-3 EPA+DHA — triglyceride and residual inflammatory risk; the only layer whose class has a positive cardiovascular outcome trial (REDUCE-IT, 4 g pure EPA).
- Nattokinase — optional fibrinolytic layer. Real acute coagulation effects, null long-term structural trial; included for completeness with its limits stated, not oversold.
The reasoning and evidence review live in the ApoB optimization article; the marker itself is explained in ApoB and Lp(a): the markers that matter. This protocol complements the mitochondrial-antioxidant approach in the cardiovascular longevity stack — that one targets bioenergetics and oxidative stress, this one targets particle count. They answer different questions.
Dosing Summary
| Layer | Supplement | Dose | Timing | Evidence |
|---|---|---|---|---|
| Synthesis | Bergamot (BPF 38%+) | 1,000 mg/day | Before meals | B |
| Clearance | Berberine | 500 mg × 3 | With meals | B |
| Triglycerides / residual risk | Omega-3 (EPA-forward) | 2 g/day | With fat | A (class) |
| Fibrinolysis (optional) | Nattokinase | 100 mg (2,000 FU) | Empty stomach | C |
The Endpoint Is ApoB
Run a baseline before the first capsule: ApoB, standard lipid panel, Lp(a) once (it's genetic), hs-CRP, HbA1c, ALT. Retest ApoB and lipids at 12 weeks.
- ApoB under 80 mg/dL is the commonly cited target for meaningful risk reduction; under 60 for aggressive goals.
- A realistic combined effect from bergamot + berberine is a 20–35% ApoB/LDL reduction — real, but roughly half of what a moderate-dose statin does alone.
- If ApoB hasn't moved by 12 weeks, the stack has failed the test. Stop paying for it and have the statin/ezetimibe conversation with your physician.
What This Protocol Cannot Do
- It does not lower Lp(a). Nothing over the counter does. If your Lp(a) is elevated, that is a physician conversation — targeted therapies are in late-stage trials, and aggressive ApoB control becomes more, not less, important.
- It is not a statin replacement for anyone with established disease, familial hypercholesterolaemia, or high calculated risk. The honest use case is primary prevention in people with moderately elevated ApoB who have already fixed diet, exercise, and sleep — or as a physician-coordinated adjunct.
- It has no outcome trial as a stack. Individual layers have biomarker RCTs; the combination is mechanistic reasoning, stated as such.
How to Build It
- Weeks 1–4: bergamot + omega-3. The best-tolerated pair; establishes the routine.
- Weeks 5–12: add berberine, one meal at a time over a week to let the gut adapt. GI upset is the common dropout reason.
- Nattokinase only if it fits your risk picture — no anticoagulants, no bleeding history, no surgery planned — and with the understanding that it is the experimental layer.
- Week 12: retest. Decide with numbers, not vibes.
Safety & Notes
- Berberine is the interaction-heavy layer: CYP3A4/2D6 inhibition affects many prescription drugs; avoid in pregnancy and with cyclosporine. Additive glucose-lowering with diabetes medication — monitor.
- Nattokinase + omega-3 both prolong bleeding time. Together they are a deliberate double bet on the same side of the coagulation ledger — tell your prescriber, and stop both two weeks before any surgery.
- Bergamot is the benign layer: heartburn at worst in trials to date.
- If you already take a statin: adding bergamot/berberine is a prescriber conversation, not a unilateral move — the studied use is dose-sparing, not replacement.
Foundations First
ApoB responds to the boring things more than to any capsule: visceral fat loss, replacing saturated fat with unsaturated, soluble fibre (psyllium alone lowers LDL ~7%), resistance training, and not smoking. The supplements above are the last 20% — run them on top of the foundations, not instead of them.